Objective:To observe the clinical effects of “Qingre Jiedu Mixture” with transcatheter arterial chemoembolization(TACE) in treating advanced hepatocellular carcinoma(HCC). MethodsSixty patients with advanced HCC were randomly divided into treatment group and control group, with 30 cases in each group. All the patients were treated with TACE, and the patients in the treatment group were treated with “Qingre Jiedu Mixture” after TACE in three to seven days for eight weeks. The effect was evaluated after eight weeks. The clinical effect of solid tumor, quality of life, toxicity reaction and survival rate were observed.  Results:The effective rates on solid tumor were 6.7%% and 3.3% respectively in the treatment group and control group; the control rates on solid tumor were 70.0%　and 63.33%　respectively in the treatment group and control group, with no statistical difference between the two groups(P>0.05). After treatment, the qualities of life, including fatigue, nausea and vomiting, appetite loss and constipation, were higher in the treatment group than in the control group(P<0.05). The incidences of nausea and vomiting were 23.3% and 50.0% in the treatment group and control group, with a statistical difference between the two groups(P<0.05). The survival rate in six months of treatment group (70.97%) was higher than that of the control group(53.33%)(P<0.05); the survival rate in one year of treatment group(45.16%) was was also higher than that of the control group(36.67%)(P<0.05).  Conclusion:“Qingre Jiedu Mixture”with TACE can enhance the quality of life, reduce the side effects of TACE and increase the survival rates in six months and one year in treating patients with advanced hepatocellular carcinoma.